Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multi-Dose Study of SGN-30 (Anti-CD30 mAb) in Patients With Refractory or Recurrent Hodgkin's Disease or Anaplastic Large Cell Lymphoma

NCT00079755 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT00079755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00079755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multi-Dose Study of SGN-30 (Anti-CD30 mAb) in Patients With Refractory or Recurrent Hodgkin's Disease or Anaplastic Large Cell Lymphoma
Lead sponsor
Seagen Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2004
Completion date
December 31, 2006
Enrollment
80
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large-cell lymphoma